Drug intelligence / Profile preview

RASAL2 siRNA

Development stage
Preclinical
Lead developer
McGill University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

RASAL2 siRNA is a small interfering RNA designed to silence the expression of the **RASAL2** (Ras protein activator like 2) gene. RASAL2 is a Ras-GTPase-activating protein that is frequently upregulated in various malignancies, such as hepatocellular carcinoma (HCC) and bladder cancer, often due to DNA hypomethylation. By targeting RASAL2 mRNA for degradation, this siRNA inhibits cancer cell proliferation, anchorage-independent growth, and invasive potential. Mechanistically, the depletion of RASAL2 suppresses the activation of the **PI3K/AKT** and **MAPK** signaling pathways, evidenced by reduced phosphorylation of AKT, JNK, MKK6, and p70S6 kinases. Additionally, RASAL2 knockdown has been shown to influence the DNA methylation machinery by down-regulating DNMT1 and MBD2, suggesting a complex role in epigenetic regulation within the tumor environment.

Other names
siRNA depletion of RASAL2RASAL2-targeting siRNARASAL-2-targeting siRNARASAL 2-targeting siRNA
02

Targets

GEF/GAP (Ras GEF / GAP family)

Beyond the preview

Go deeper on RASAL2 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RASAL2 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call